

## **Focusing for success: A new Olink company organization to meet our future ambitions**

**Uppsala, Sweden, April 12, 2016** - Olink AB has gone through a formal reorganization, and as of April 1, 2016 is operating as two separate companies, each with its own distinct focus area.

**Olink Proteomics** will continue to expand and develop the Proseek® Multiplex product line for human protein biomarker discovery. With all the company's resources fully dedicated towards this flagship precision proteomics platform, Olink Proteomics aims to provide its customers with an ever-expanding range of high quality multiplex immunoassays for biomarker discovery, and support the future development of diagnostic tools based on clinically relevant protein signatures. This singular focus on Proseek demonstrates Olink Proteomics' absolute commitment to provide the best possible solutions for our current and future customers in the protein biomarker field.

The CEO for Olink Proteomics AB is Lotta Falck

Email: [lotta.falck@olink.com](mailto:lotta.falck@olink.com)

Web: [www.olinkproteomics.com](http://www.olinkproteomics.com)

Phone +46 702 71 01 07

**Olink Bioscience** will focus on developing and commercializing the many additional technologies held within Olink's extensive and growing, diverse IP portfolio. With a strong R&D team dedicated to developing these new technologies in collaboration with scientists at Uppsala University, Olink Bioscience aims to continue its successful work providing access to new and innovative molecular tools for life science researchers and for molecular diagnostics.

The CEO for Olink Bioscience is Peter Åsberg

Email: [peter.asberg@olinkbioscience.com](mailto:peter.asberg@olinkbioscience.com)

Web: [www.olinkbioscience.com](http://www.olinkbioscience.com)

Phone +46 709 49 17 21

This reorganization of Olink's wider business will enable each of the two new companies to focus 100% on its primary objective, with fully dedicated resources and a clear sense of direction.

"The company division reflects both the desire to best serve the needs and expectations of customers in our rapidly growing Proseek business, and the deep seated commitment to develop exciting new molecular tools for the wider scientific community. Both of these can now be pursued with total focus and without compromise" say Andrea Ballagi, VP Sales & Marketing at Olink Proteomics and Peter Åsberg, CEO at Olink Bioscience.

If you have questions about this reorganization, please contact Magnus Eriksson, Chief Financial Officer, Olink Proteomics:

E-mail: [magnus.eriksson@olink.com](mailto:magnus.eriksson@olink.com)

Phone +46 18 444 39 70

### **Product and technology information**

Proseek Multiplex is based on the proprietary **Proximity Extension Assay (PEA) technology** developed by Olink. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules, which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective target protein. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR. This dual recognition, DNA-coupled method provides exceptional readout specificity, enabling Proseek Multiplex to achieve a combination of high multiplexing and excellent data quality that cannot be matched using standard immunoassay techniques. An animation illustrating how the technology works and what it is used for can be [viewed on our YouTube channel](#).

# Press Release

For research use only. Not for use in diagnostic procedures.

Olink Proteomics and Olink Bioscience are headquartered in Uppsala, Sweden.

For more information, please visit [www.olink.com](http://www.olink.com).

Olink and Proseek are registered trademarks of Olink AB.